ClinicalTrials.gg
CompletedNCT00382720Updated Jan 7, 2013Results posted

Docetaxel and Oxaliplatin in Gastric Cancer

A Phase 2 interventional study of Docetaxel + Oxaliplatin and Docetaxel + Oxaliplatin + 5-FU in Stomach Neoplasms, sponsored by Sanofi. Completed at 12 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-07.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
275
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 103 studies testing docetaxel in Stomach Neoplasms — 9 open to participants now, 13 under way, 5 of them phase 3. Docetaxel · Stomach Neoplasms.

Enrollment
8th of 99
275 · median 50
Started
2006
with 10 others
Phase 2
71 of 103
3 open now
Registered
19th of 103
by date
Lead sponsor
6 of 103
Sanofi

Among the 103 studies testing docetaxel in Stomach Neoplasms, this one is the 8th largest by enrollment of the 99 interventional ones that give a count, is one of 11 that started in 2006, is one of 71 in phase 2, and was the 19th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

9 of the 103 studies testing docetaxel in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies testing docetaxel in Stomach Neoplasms, or all of them as a file.
02

Study summary

This phase II study addressed the use of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. Prior to this study a pilot phase I (part I) determined the optimal dose by assessing the safety and tolerability of 2 dose levels in each arm. The optimal dose was administered in the Part II study. Participants who received the optimal dose in each treatment arm in Part I were included in the Part II analysis population.

Primary objective:

  • To assess the time to progression (TTP) of Docetaxel in combination with Oxaliplatin with or without 5-Fluorouracil (5-FU) or Capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease (part II).

Secondary objectives:

  • To establish the safety profile.
  • To assess the Overall Response Rate (ORR) based on the World Health Organization (WHO) criteria
  • To assess the Overall Survival (OS)
Read the detailed description

The purpose of this study (Part II) was to evaluate the time to progression in the 3 arms at an optimal dose level of docetaxel and oxaliplatin defined during a prior pilot (Part I) phase study. The estimated duration of treatment was to be 6 months. Treatment was to be administered up to progression, unacceptable toxicities, or withdrawal of consent. The reason and date of removal of all participants was documented on the case report form.

Participants who ended treatment but had not yet progressed (e.g. unacceptable toxicities or withdrawal of consent) were be followed every 8 weeks with a complete tumor assessment until documented progression or further anti-tumor therapy. Then, they would be followed every 3 months after progression for survival status; date of death or progression were reported. Participants who ended treatment for progression, were to be followed every 3 months until death. Date of death was reported. The planned duration of the study was 30 months.

03

Conditions studied

  • Stomach Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven gastric adenocarcinoma, including adenocarcinoma of the gastro-oesophageal junction
  • or locally recurrent disease
  • Prior (and/or neo-adjuvant) chemotherapy with 5-Fluorouracil, Cisplatin, epirubicin is allowed provided that the patient has > 12 months after the end of the chemotherapy
  • Performance status index > 70
  • Hematology within 7 days before randomization: ≥10g/dl, ≥2.0 10\^9/L, ≥100 x 10\^9/L
  • Blood chemistry within 7 days before randomization:Total ≤1x Upper Normal Limit(UNL), (AST) Serum Glutamic Oxaloacetic Transaminase SGOT) and Alanine Aminotransferase (ALT)Serum Glutamate Pyruvate Transaminase(SGPT) ≤2.5xUNL, alkaline phosphatase ≤ 5x UNL, provided that AST or ALT > 1.5 x UNL is not associated with alkaline phosphatase > 2.5 x UNL; creatinine ≤1.25x UNL or 1.25x UNL \< creatinine ≤1.5x UNL and calculated/measured ≥60 ml/min)
  • Measurable and/or evaluable metastatic disease

Exclusion criteria

Exclusion criteria:

  • Any prior palliative chemotherapy
  • Neurosensory symptoms National Cancer Institute Common Toxicity Criteria for Adverse Events grade≥2

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
275 participants (actual)

Study arms

  • Experimental
    TE (Taxotere and Eloxatin)

    Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin). Each chemotherapy cycle was repeated every 21 days. Participants received either the optimal or non-optimal dose for Taxotere and Eloxatin. Participants who received the optimal dose for Taxotere and Eloxatin were analyzed in this study.

    Drug: Docetaxel + Oxaliplatin

  • Experimental
    TEF (Taxotere, Eloxatin and 5-FU)

    Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and 5-FU (5-Fluorouracil). Each chemotherapy cycle was repeated every 14 days. Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and 5-FU. Participants who received the optimal dose for Taxotere, Eloxatin and 5-FU were analyzed in this study.

    Drug: Docetaxel + Oxaliplatin + 5-FU

  • Experimental
    TEX (Taxotere, Eloxatin and Xeloda)

    Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and capecitabine (Xeloda). Each chemotherapy cycle was repeated every 21 days. Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and Xeloda. Participants who received the optimal dose for Taxotere, Eloxatin and Xeloda were analyzed in this study.

    Drug: Docetaxel + Oxaliplatin + Capecitabine

Interventions

  • DrugDocetaxel + Oxaliplatin

    Drug pages: Docetaxel · Oxaliplatin

    Dose level 1 (non-optimal dose): Docetaxel 75 mg/m² as an 1-hour intravenous (IV) infusion on day 1 followed by Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1 Dose level 2 (optimal dose): Docetaxel 75 mg/m² as an 1-hour IV infusion on day 1 followed by Oxaliplatin 130 mg/m² as a two to six-hour IV infusion on day 1

  • DrugDocetaxel + Oxaliplatin + 5-FU

    Drug pages: Docetaxel · Oxaliplatin · Fluorouracil

    Dose level 1 (non-optimal dose): Docetaxel 40 mg/m² as a 1-hour intravenous (IV) infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m2 as a 46-hour continuous infusion day 1. Dose level 2 (optimal dose): Docetaxel 50 mg/m² as a 1-hour IV infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m² as a 46-hour continuous infusion day 1.

  • DrugDocetaxel + Oxaliplatin + Capecitabine

    Drug pages: Docetaxel · Oxaliplatin · Capecitabine

    Dose level 1 (optimal dose): Docetaxel 50 mg/m² as a 1-hour intravenous (IV) infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m2 two times a day continuously. Dose level 2 (non-optimal dose): Docetaxel 65 mg/m² as a 1-hour IV infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m² two times a day continuously.

06

What researchers measure

Primary outcomes

  1. Time to Progression

    The number of months measured from the day of randomization to the first tumor progression according to World Health Organization (WHO) criteria evaluation of cancer response, or death from any cause. WHO Criteria for Progressive Disease: ≥ 25% increase in the size of at least one bidimensionally or unidimensionally measurable lesion.

    Time frame: every 8 weeks up to a maximum of 36 months

Secondary outcomes

  1. Best Overall Response Rate (ORR)

    Percentage of partial and complete responses, according to WHO criteria: Complete Response: Disappearance of all known disease, determined by 2 observations not less than 4 weeks apart. Partial Response: Decrease by at least 50% of the diameters of all measurable lesions, determined by 2 observations not less than 4 weeks apart.

    Time frame: every 8 weeks up to a maximum of 36 months

  2. Overall Survival (OS)

    The number of months measured from the date of randomization to the date of death due to any cause.

    Time frame: up to a maximum of 36 months

07

Results

Posted Aug 10, 2011

Participant flow

A total 275 participants from 12 countries were randomized in the part I/II study. 64 participants were enrolled in Part I. 211 new participants were enrolled specifically for Part II.

Participant flow — Overall Study
Milestone(TE) Taxotere and Eloxatin(TEF) Taxotere, Eloxatin and 5-fluorouracil(TEX) Taxotere, Eloxatin and Xeloda
Started798986
Administered non-optimal dose (part i)10110
Administered optimal dose (parts i & ii)788882
Full analysis population (fap)788882
Completed000
Not completed798986
Withdrew: Adverse event212315
Withdrew: Protocol violation251
Withdrew: Death012
Withdrew: Progressive disease372838
Withdrew: Withdrew consent112
Withdrew: Withdrawal by subject112012
Withdrew: Surgery114
Withdrew: Patient did not receive study medication114
Withdrew: Clinically progressive disease010
Withdrew: Good prognosis010
Withdrew: Investigator/clinical decision566
Withdrew: Discontinued at end of study012

Outcome measures

PrimaryTime to Progression

The number of months measured from the day of randomization to the first tumor progression according to World Health Organization (WHO) criteria evaluation of cancer response, or death from any cause. WHO Criteria for Progressive Disease: ≥ 25% increase in the size of at least one bidimensionally or unidimensionally measurable lesion.

Time frame:
every 8 weeks up to a maximum of 36 months
Reported as:
Median · Months
Time to Progression
Months(TE) Taxotere and Eloxatin(TEF) Taxotere, Eloxatin and 5-fluorouracil(TEX) Taxotere, Eloxatin and Xeloda
Time to Progression4.50 (3.68 to 5.32)7.66 (6.97 to 9.40)5.55 (4.30 to 6.37)
SecondaryBest Overall Response Rate (ORR)

Percentage of partial and complete responses, according to WHO criteria: Complete Response: Disappearance of all known disease, determined by 2 observations not less than 4 weeks apart. Partial Response: Decrease by at least 50% of the diameters of all measurable lesions, determined by 2 observations not less than 4 weeks apart.

Time frame:
every 8 weeks up to a maximum of 36 months
Reported as:
Number · percentage of participants
Best Overall Response Rate (ORR)
percentage of participants(TE) Taxotere and Eloxatin(TEF) Taxotere, Eloxatin and 5-fluorouracil(TEX) Taxotere, Eloxatin and Xeloda
Best Overall Response Rate (ORR)23.1 (14.3 to 34.0)46.6 (35.9 to 57.5)25.6 (16.6 to 36.4)
SecondaryOverall Survival (OS)

The number of months measured from the date of randomization to the date of death due to any cause.

Time frame:
up to a maximum of 36 months
Reported as:
Median · months
Overall Survival (OS)
months(TE) Taxotere and Eloxatin(TEF) Taxotere, Eloxatin and 5-fluorouracil(TEX) Taxotere, Eloxatin and Xeloda
Overall Survival (OS)8.97 (7.79 to 10.87)14.59 (11.70 to 21.78)11.30 (8.08 to 14.03)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
(TE) Taxotere and Eloxatin—35/78 (44.9%)75/78 (96.2%)
(TEF) Taxotere, Eloxatin and 5-fluorouracil—24/88 (27.3%)87/88 (98.9%)
(TEX) Taxotere, Eloxatin and Xeloda—36/82 (43.9%)77/82 (93.9%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
Event(TE) Taxotere and Eloxatin(TEF) Taxotere, Eloxatin and 5-fluorouracil(TEX) Taxotere, Eloxatin and Xeloda
diarrheaGastrointestinal disorders7/783/882/82
febrile neutropeniaBlood and lymphatic system disorders7/782/885/82
pulmonary embolismRespiratory, thoracic and mediastinal disorders4/781/882/82
general physical health deteriorationGeneral disorders3/781/881/82
vomitingGastrointestinal disorders2/783/883/82
decreased appetiteMetabolism and nutrition disorders0/780/883/82
anemiaBlood and lymphatic system disorders2/780/881/82
pyrexiaGeneral disorders2/781/880/82
gastroenteritisInfections and infestations2/780/880/82
dehydrationMetabolism and nutrition disorders2/780/881/82
Most frequent other events
Showing 10 of 45
Most frequent other events
Event(TE) Taxotere and Eloxatin(TEF) Taxotere, Eloxatin and 5-fluorouracil(TEX) Taxotere, Eloxatin and Xeloda
diarrhoeaGastrointestinal disorders48/7859/8853/82
nauseaGastrointestinal disorders45/7852/8843/82
alopeciaSkin and subcutaneous tissue disorders25/7847/8836/82
fatigueGeneral disorders35/7845/8839/82
vomitingGastrointestinal disorders36/7830/8830/82
decreased appetiteMetabolism and nutrition disorders32/7836/8837/82
stomatitisGastrointestinal disorders19/7839/8821/82
peripheral sensory neuropathyNervous system disorders27/7833/8825/82
abdominal painGastrointestinal disorders24/7819/8816/82
astheniaGeneral disorders21/7822/8816/82

Baseline characteristics

Age Continuous
Age Continuous(years)(TE) Taxotere and Eloxatin(TEF) Taxotere, Eloxatin and 5-fluorouracil(TEX) Taxotere, Eloxatin and XelodaTotal
Mean59.2 ± 11.457.9 ± 11.159.0 ± 11.058.7 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)(TE) Taxotere and Eloxatin(TEF) Taxotere, Eloxatin and 5-fluorouracil(TEX) Taxotere, Eloxatin and XelodaTotal
Female28282278
Male516164176
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)(TE) Taxotere and Eloxatin(TEF) Taxotere, Eloxatin and 5-fluorouracil(TEX) Taxotere, Eloxatin and XelodaTotal
Asian/Oriental0101
Black1001
White778784248
Unknown or Not Reported1124
Karnofsky Performance Status (KPS)
Karnofsky Performance Status (KPS)(participants)(TE) Taxotere and Eloxatin(TEF) Taxotere, Eloxatin and 5-fluorouracil(TEX) Taxotere, Eloxatin and XelodaTotal
100% Normal, no complaints: no evidence of disease19281966
90% Able to carry on normal activity; minor signs26353192
80% Normal activity with effort, some signs31243388
70% Cares for self but unable to work1236
<70% Requires assistance1001
Missing1001
Weight loss during last 3 months
Weight loss during last 3 months(participants)(TE) Taxotere and Eloxatin(TEF) Taxotere, Eloxatin and 5-fluorouracil(TEX) Taxotere, Eloxatin and XelodaTotal
less than or equal to 5%394744130
greater than 5%394241122
Missing1012
08

Study locations

12 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey, United States
  • Sanofi-Aventis Administrative Office
    Diegem, Belgium
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Frankfurt, Germany
  • Sanofi-Aventis Administrative Office
    Budapest, Hungary
  • Sanofi-Aventis Administrative Office
    Milan, Italy
  • Sanofi-Aventis Administrative Office
    Porto Salvo, Portugal
  • Sanofi-Aventis Administrative Office
    Moscow, Russian Federation
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Genève, Switzerland
  • Sanofi-Aventis Administrative Office
    Istanbul, Turkey
  • Sanofi-Aventis Administrative Office
    Guildford Surrey, United Kingdom
09

References and documents

Publications

  • Van Cutsem E, Boni C, Tabernero J, Massuti B, Middleton G, Dane F, Reichardt P, Pimentel FL, Cohn A, Follana P, Clemens M, Zaniboni A, Moiseyenko V, Harrison M, Richards DA, Prenen H, Pernot S, Ecstein-Fraisse E, Hitier S, Rougier P. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol. 2015 Jan;26(1):149-156. doi: 10.1093/annonc/mdu496. PubMed 25416687 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2006
First posted
Sep 29, 2006
Start
Sep 2006
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Results first posted
Aug 10, 2011
Last update
Jan 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00382720
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 29, 2006
Start date
Sep 2006
Primary completion
Apr 2010
Completion
Apr 2010
Results posted
Aug 10, 2011
Last update
Jan 7, 2013

Study contacts

Jean-Philippe Aussel
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Oxaliplatin · Fluorouracil · Capecitabine

Start the discussion